Ácido Ascórbico como adjuvante no tratamento de anemia em pacientes com Doença Renal Crônica sob Hemodiálise: revisão integrativa da literatura
DOI:
https://doi.org/10.33448/rsd-v11i4.27155Palavras-chave:
Ácido Ascórbico; Anemia; Diálise Renal; Doença renal crônica.Resumo
Objetivo: investigar na literatura as evidências científicas sobre os efeitos do Ácido Ascórbico em desfechos bioquímicos tais como hemoglobina, ferritina e saturação de transferrina em pacientes com doença renal crônica submetidos à terapia renal substitutiva. Métodos: Trata-se de um estudo de Revisão Integrativa da Literatura com abordagem qualitativa. Utilizaram-se as bases de dados; Literatura Latino-Americana em Ciências da Saúde (LILACS), Medical Literature and Retrieval System on Line (Medline), Excerpta Médica dataBASE (EMBASE), Cochrane Library. Foram incluídos 11 estudos, apenas ensaios clínicos que utilizaram o ácido ascórbico em pacientes sob hemodiálise e analisaram seus efeitos. Resultados: Os achados corroboram para a eficácia do Ácido Ascórbico como adjuvante no tratamento da anemia em pacientes submetidos em tratamento de hemodiálise, uma vez que aumenta a hemoglobina sérica e reduz a necessidade da Eritropoetina Recombinante Humana. Alé disso, retratam a redução dos níveis de ferritina sérica e a elevação da saturação de transferrina, fato que eleva sua biodisponibilidade e ser útil na deficiência funcional de ferro. Conclusão: Embora os estudos sejam limitados pelo pequeno número de participantes, curta duração do seguimento após a intervenção e variabilidade de qualidade, o Ácido Ascórbico se apresenta como eficaz como coadjuvante no controle da anemia. Estudos mais prolongados são necessários para confirmar estes resultados, relatar eventos adversos e determinar o impacto nos desfechos a longo prazo.
Referências
Agarwal, N., & Prchal, J. T. (2009). Anemia of chronic disease (anemia of inflammation). Acta haematologica, 122(2-3), 103–108. https://doi.org/10.1159/00024379434.
Attallah, N., Osman-Malik, Y., Frinak, S., & Besarab, A. (2006). Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia. American journal of kidney diseases: the official journal of the National Kidney Foundation, 47(4), 644–654. https://doi.org/10.1053/j.ajkd.2005.12.025
Candan, F., Gültekin, F., & Candan, F. (2002). Effect of vitamin C and zinc on osmotic fragility and lipid peroxidation in zinc-deficient haemodialysis patients. Cell biochemistry and function, 20(2), 95–98. https://doi.org/10.1002/cbf.947
Chan, D., Irish, A., & Dogra, G. (2005). Efficacy, and safety of oral versus intravenous ascorbic acid for anaemia in haemodialysis patients. Nephrology 10(4):336-40. 10.1111/j.1440-1797.2005.00424. x. PMID: 16109077.
Deicher, R., Ziai, F., Bieglmayer, C., Schillinger, M., & Hörl, W. H. (2005). Low total vitamin C plasma level is a risk factor for cardiovascular morbidity and mortality in hemodialysis patients. Journal of the American Society of Nephrology: JASN, 16(6), 1811–1818. https://doi.org/10.1681/ASN.2004100850
Descombes, E., Hanck, A. B., & Fellay, G. (1993). Water soluble vitamins in chronic hemodialysis patients and need for supplementation. Kidney international, 43(6), 1319–1328. https://doi.org/10.1038/ki.1993.185
Deved, V., Poyah, P., James, M. T., Tonelli, M., Manns, B. J., Walsh, M., Hemmelgarn, B. R., & Alberta Kidney Disease Network (2009). Ascorbic acid for anemia management in hemodialysis patients: a systematic review and meta-analysis. American journal of kidney diseases: the official journal of the National Kidney Foundation, 54(6), 1089–1097. https://doi.org/10.1053/j.ajkd.2009.06.040
Drüeke T.B., Locatelli F., Clyne N., Eckardt K.U., Macdougall I.C., Tsakiris D. (2006); CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355:2071-84.
Ebben, J. P., Gilbertson, D. T., Foley, R. N., & Collins, A. J. (2006). Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations. Clinical journal of the American Society of Nephrology: CJASN, 1(6), 1205–1210. https://doi.org/10.2215/CJN.0111030630
Gafter-Gvili, A., Schechter, A., & Rozen-Zvi, B. (2019). Iron Deficiency Anemia in Chronic Kidney Disease. Acta haematologica, 142(1), 44–50. https://doi.org/10.1159/ 000496492
Gillis, K., Stevens, K. K., Bell, E., Patel, R. K., Jardine, A. G., Morris, S. T. W., Schneider M. P., Delles C., & Mark P. B. (2018). Ascorbic acid lowers central blood pressure and asymmetric dimethylarginine in chronic kidney disease. Clin Kidney J. 11(4) 532-539. 10.1093/ckj/sfx158.
Grotto, H. Z. W. (2008). Metabolismo do ferro: uma revisão sobre os principais mecanismos envolvidos em sua homeostase. Revista Brasileira de Hematologia e Hemoterapia, 30(5), 390-397. < https://doi.org/10.1590/S1516-84842008000500012.
Handelman G. J. (2007). Vitamin C deficiency in dialysis patients--are we perceiving the tip of an iceberg? Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association, 22(2), 328–331. https://doi.org/10.1093/ndt/gfl53435.
Kang, D.W., Ahn, C.Y., Ryu, B.K., Shin, B.C., Chung, J.H., & Kim, H. L. (2012). The effect of intravenous ascorbic acid in hemodialysis patients with normoferritinemic anemia. Kidney Res Clin Pract.31(1):48-53. 10.1016/j.krcp.2012.01.002.
Kawabata, H., Yang, R., Hirama, T., Vuong, P. T., Kawano, S., Gombart, A. F., & Koeffler, H. P. (1999). Molecular cloning of transferrin receptor 2. A new member of the transferrin receptor-like family. The Journal of biological chemistry, 274(30), 20826–20832. https://doi.org/10.1074/jbc.274.30.20826
Keven, K., Kutlay, S., Nergizoglu, G., & Ertürk, S. (2003). Randomized, crossover study of the effect of vitamin C on EPO response in hemodialysis patients. American journal of kidney diseases: the official journal of the National Kidney Foundation, 41(6), 1233–1239. https://doi.org/10.1016/s0272-6386(03)00356-1
Kidney Disease: Improving Global Outcomes (KDIGO) (2012). Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney inter., 2: 308.
Kuragano, T., Yahiro, M., Kida, A., Furuta, M., Nagasawa, Y., Hasuike, Y., Nanami, M., & Nakanishi, T. (2014). Effect of protoconized therapy for renal anemia on adverse events of patients with maintenance hemodialysis. The International journal of artificial organs, 37(12), 865–874. https://doi.org/10.5301/ijao.5000370.
Lin, C. L., Hsu, P. Y., Yang, H. Y., & Huang, C. C. (2003). Low dose intravenous ascorbic acid for erythropoietin-hyporesponsive anemia in diabetic hemodialysis patients with iron overload. Renal failure, 25(3), 445–453. https://doi.org/10.1081/jdi-120021157
Locatelli, F., Bárány, P., Covic, A., De Francisco, A., Del Vecchio, L., Goldsmith, D., Hörl, W., London, G., Vanholder, R., Van Biesen, W., & ERA-EDTA ERBP Advisory Board (2013). Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association, 28(6), 1346–1359. https://doi.org/10.1093/ndt/gft033
Locatelli, F., Canaud, B., Eckardt, K. U., Stenvinkel, P., Wanner, C., & Zoccali, C. (2003). Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association, 18(7), 1272–1280. https://doi.org/10.1093/ndt/gfg074
Manela-Azulay, M.; Mandarim-de-Lacerda, C. A.; Perez, M. A.; Filgueira, A. L.; Cuzzi, T. (2003) Vitamina C. Anais Brasileiros de Dermatologia 78(3) https://doi.org/10.1590/S0365-05962003000300002.
Oliveira Júnior, W. V., Sabino, A. P., Figueiredo, R. C., & Rios, D. R. A. (2015). Inflamação e má resposta ao uso de eritropoetina na doença renal crônica. Braz. J. Nephrol., 37(2), 255-263.
Palmer, S. C., Saglimbene, V., Mavridis, D., Salanti, G., Craig, J. C., Tonelli, M., Wiebe, N., & Strippoli, G. F. (2014). Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. The Cochrane database of systematic reviews, 2014(12), CD010590. https://doi.org/10.1002/14651858.CD010590.pub2
Pfeffer M. A., Burdmann E. A., Chen C. Y., Cooper M. E., de Zeeuw D., Eckardt K. U.. (2009); TREAT Investigators. A trial of Darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361:2019-32. PMID: 19880844 (Correction of Hemoglobin and Outcomes in Renal Insufficiency) trial. Am J Kidney Dis 2012 Sep; 60:390
Pisoni, R. L., Bragg-Gresham, J. L., Young, E. W., Akizawa, T., Asano, Y., Locatelli, F., Bommer, J., Cruz, J. M., Kerr, P. G., Mendelssohn, D. C., Held, P. J., & Port, F. K. (2004). Anemia management and outcomes from twelve countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). American journal of kidney diseases: the official journal of the National Kidney Foundation, 44(1), 94–111. https://doi.org/10.1053/j.ajkd.2004.03.023.
Richter, A., Kuhlmann, M. K., Seibert, E., Kotanko, P., Levin, N. W., & Handelman, G. J. (2008). Vitamin C deficiency and secondary hyperparathyroidism in chronic haemodialysis patients. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association, 23(6), 2058–2063. https://doi.org/10.1093/ndt/gfn084
Sedighi, O., Makhlough, A., Janbabai, G., Neemi, M. (2013). Comparative study of intravenous iron versus intravenous ascorbic Acid for treatment of functional iron deficiency in patients under hemodialysis: a randomized clinical trial. Nephrourol Mon;5(4):913-917. 10.5812/numonthly.12038
Sezer, S., Ozdemir, F. N., Yakupoglu, U., Arat, Z., Turan, M., & Haberal, M. (2002). Intravenous ascorbic acid administration for erythropoietin-hyporesponsive anemia in iron loaded hemodialysis patients. Artificial organs, 26(4), 366–370. https://doi.org/10.1046/j.1525-1594.2002.06888.x
Shahrbanoo K., & Taziki O. (2008). Effect of intravenous ascorbic acid in hemodialysis patients with anemia and hyperferritinemia. Saudi J Kidney Dis Transpl. 2008 Nov;19(6):933-6.
Sing A.K., Szczech L., Tang K.L., Barnhart H., Sapp S., & Wolfson M. (2006); CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355:2085-98.
Sirover, W. D., Liu, Y., Logan, A., Hunter, K., Benz, R. L., Prasad, D., Avila, J., Venkatchalam, T., Weisberg, L. S., & Handelman, G. J. (2015). Plasma ascorbic acid concentrations in prevalent patients with end-stage renal disease on hemodialysis. Journal of renal nutrition: the official journal of the Council on Renal Nutrition of the National Kidney Foundation, 25(3), 292–300. https://doi.org/10.1053/j.jrn.2014.09.007.
Sirover, W. D., Siddiqui, A. A., & Benz, R. L. (2008). Beneficial hematologic effects of daily oral ascorbic acid therapy in ESRD patients with anemia and abnormal iron homeostasis: a preliminary study. Renal failure, 30(9), 884–889. https://doi.org/10.1080/08860220802353884
Tanaka, M., Komaba, H., & Fukagawa, M. (2018). Emerging Association Between Parathyroid Hormone and Anemia in Hemodialysis Patients. Therapeutic apheresis and dialysis: official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 22(3), 242–245. https://doi.org/10.1111/1744-9987.12685
Tarng, D. C., & Huang, T. P. (1998). A parallel, comparative study of intravenous iron versus intravenous ascorbic acid for erythropoietin-hyporesponsive anaemia in haemodialysis patients with iron overload. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association, 13(11), 2867–2872. https://doi.org/10.1093/ndt/13.11.2867.
Tarng, D. C., Wei, Y. H., Huang, T. P., Kuo, B. I., & Yang, W. C. (1999). Intravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia. Kidney international, 55(6), 2477–2486. https://doi.org/10.1046/j.1523-1755.1999.00479.x
Valderrábano F. (2002). Anaemia management in chronic kidney disease patients: an overview of current clinical practice. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association, 17 Suppl 1, 13–18. https://doi.org/10.1093/ndt/17.suppl_1.13
Wang, S., Eide, T. C., Sogn, E. M., Berg, K. J., & Sund, R. B. (1999). Plasma ascorbic acid in patients undergoing chronic haemodialysis. European journal of clinical pharmacology, 55(7), 527–532. https://doi.org/10.1007/s002280050668
Washio, K., Inagaki, M., Tsuji, M., Morio, Y., Akiyama, S., Gotoh, H., Gotoh, T., Gotoh, Y., & Oguchi, K. (2008). Oral vitamin C supplementation in hemodialysis patients and its effect on the plasma level of oxidized ascorbic acid and Cu/Zn superoxide dismutase, an oxidative stress marker. Nephron. Clinical practice, 109(2), c49–c54. https://doi.org/10.1159/000137628
Whittemore R., & Knafl K. (2005). The integrative review: updated methodology. J Adv Nurs. 52(5):546-53.
Zhang, K., Liu, L., Cheng, X., Dong, J., Geng, Q., & Zuo, L. (2011). Low levels of vitamin C in dialysis patients are associated with decreased prealbumin and increased C-reactive protein. BMC nephrology, 12, 18. https://doi.org/10.1186/1471-2369-12-18
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2022 Kleber Luiz da Fonseca Azevedo; Eudes Euler de Lucena Souza; Micássio Fernandes Andrade
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Autores que publicam nesta revista concordam com os seguintes termos:
1) Autores mantém os direitos autorais e concedem à revista o direito de primeira publicação, com o trabalho simultaneamente licenciado sob a Licença Creative Commons Attribution que permite o compartilhamento do trabalho com reconhecimento da autoria e publicação inicial nesta revista.
2) Autores têm autorização para assumir contratos adicionais separadamente, para distribuição não-exclusiva da versão do trabalho publicada nesta revista (ex.: publicar em repositório institucional ou como capítulo de livro), com reconhecimento de autoria e publicação inicial nesta revista.
3) Autores têm permissão e são estimulados a publicar e distribuir seu trabalho online (ex.: em repositórios institucionais ou na sua página pessoal) a qualquer ponto antes ou durante o processo editorial, já que isso pode gerar alterações produtivas, bem como aumentar o impacto e a citação do trabalho publicado.
